ReviewCurrent oncology reports2015
Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.
Review in Current oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Choroidal metastasis of testicular choriocarcinoma: a case report and meta-analysis.American journal of ophthalmology case reports · 2026Article
- Predictors of First-Line Progression-Free Survival in Testicular Germ Cell Tumors: A Retrospective Cohort Study.Cancers · 2026Article
- New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Microdissection testicular sperm extraction for men with nonobstructive azoospermia who have a testicular tumor in situ at the time of sperm retrieval.Asian journal of andrology · 2025Review
- A Complex Case of Testicular Choriocarcinoma in Cryptorchidism and Choriocarcinoma Syndrome: Clinical and Treatment Insights.The American journal of case reports · 2025Article
- Male choriocarcinoma presenting with intracerebral hemorrhage: a case report and literature review.Frontiers in oncology · 2025Article
- Case report: A case with atypical presentation oftesticular choriocarcinoma.Frontiers in oncology · 2024Article
- Pure testicular choriocarcinoma, a rare and highly malignant subtype with challenging treatment: A case report and review of the literature.Molecular and clinical oncology · 2024Article
- A poor prognostic male choriocarcinoma with multiple systemic metastases: a case report and the literature review.Frontiers in medicine · 2024Article
- A decade in focus: mixed germ cell tumors with choriocarcinoma components.Annals of medicine and surgery (2012) · 2023Article
- Pure testicular choriocarcinoma with gastrointestinal metastasis and paraneoplastic symptoms: a case report.BMC urology · 2023Article
- Article
- Testicular choriocarcinoma with small bowel metastasis and active gastrointestinal bleeding.Radiology case reports · 2023Article
- The Role of microRNAs in the Gonocyte Theory as Target of Malignancy: Looking for Potential Diagnostic Biomarkers.International journal of molecular sciences · 2022Review
- Gastrointestinal bleeding caused by metastatic testicular choriocarcinoma: a case report and literature review.World journal of surgical oncology · 2022Review
- International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.Ecancermedicalscience · 2022Article
- A 26-year old young male with severe anemia.Respiratory medicine case reports · 2022Article
- Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center.Cancer research and treatment · 2021Article
- An Exceptionally Rare Cause of Refractory Gastrointestinal Bleed: Choriocarcinoma Syndrome.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular germ cell tumors represent the most common malignancy among young men. While 5-year overall survival and cure for this population is greater than 95%, choriocarcinoma is an aggressive subtype of this disease with far worse prognosis--5-year survival for choriocarcinoma is less than 80%. In order to be able to treat these patients appropriately, a provider must recognize characteristic features of choriocarcinoma including elevated human chorionic gonadotropin in a young man with testicular mass; the astute clinician should also know the signs and symptoms of choriocarcinoma syndrome, characterized by bleeding from metastatic sites, which represents a medical emergency and is associated with high morbidity and mortality. Treatment should be directed towards a goal of tumor marker normalization, and patients with refractory disease should be considered for advanced therapies and clinical trials. Choriocarcinoma is a unique and aggressive germ cell malignancy, and these patients require early aggressive treatment to improve their chance of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.